Spotlight on Pediatrics

Credits: 0.50 CME
Spinal Muscular Atrophy Expert Discussion Conference Series — Transformative Treatment for SMA
Eugenio Mercuri, MD, PhD
The France Foundation

Spinal Muscular Atrophy Expert Discussion Conference Series — Transformative Treatment for SMA

Start

Conference Series: Part 2 of 3

Activity Details

Free CME
0.50 AMA PRA Category 1 Credit(s)
Released: August 21, 2018
Expires: August 20, 2019
30 minutes to complete

Accredited By

Target Audience

Neurologists, pediatric neurologists, neuromuscular specialists, pediatricians, genetic counselors, and other clinicians who see patients with spinal muscular atrophy

Learning Objectives

  • Explore the potential implications of gene therapy for SMA
  • Summarize key clinical trial data on available/emerging treatments for SMA

Activity Description

As new therapies emerge for spinal muscular atrophy (SMA) that include gene replacement and gene modifying therapies, clinicians need to consider the expectations for these treatments. Experts, Dr. Eugenio Mercuri, Dr. Richard Finkel, and Dr. Gyula Acsadi, recently discussed these emerging therapies and their implications on the clinical disease state at an international meeting. This activity is a recording of their roundtable discussion with informative slides broken into 3 parts. The first part discusses diagnosis, genetics, and the role of SMN in SMA. Part 2 explains the results of emerging clinical trial data. The final activity is a practical discussion about the implications of these new therapies for this lethal disease. Discussion topics include the durability of new and emerging treatments and changes to the standards of care for patients with SMA. This education is an engaging update on SMA from the leading experts in the field.

Statement of Educational Need

Many clinicians have questions regarding the genetics of spinal muscular atrophy. In addition, carrier screening is not routinely done, despite ACOG recommendations. Routine newborn testing is currently being considered in many states and internationally. Identification of the neuromotor deficits associated with SMA (and other conditions) is often inaccurate or delayed. As new therapies emerge that include gene replacement and gene modifying therapies, clinicians need to consider the expectations of these treatments. Gene replacement therapy is still a mystery to most clinicians. New therapies prompt a reevaluation of current standards of SMA care.

Agenda

  • Gene splicing modifiers
  • Gene replacement therapy MOA
  • Clinical trial results

Faculty

Eugenio Mercuri, MD, PhD (Chair)
Professor of Pediatric Neurology
Catholic University of the Sacred Heart
Rome, Italy

Dr. Eugenio Mercuri is a consultant for AveXis, Biogen, F. Hoffmann-La Roche, and IONIS. He is a principal investigator for Biogen/IONIS and F. Hoffmann-La Roche studies.


Richard S. Finkel, MD
Division Chief of Neurology
Pediatric Neurology
Nemours Children’s Hospital
Orlando, Florida, United States

Dr. Richard Finkel is a consultant for AveXis, Biogen, Catabasis, Ionis, Mitobridge, Novartis, and Roche. He receives clinical trial support from AveXis, Biogen, Catabasis, Cytokinetics, Ionis, Lilly, MDA, NIH, ReveraGen, and Summit. Dr. Finkel owns stock in Roche. His partner holds several patents and receives patent licensing royalties from National Jewish Center and Children’s Hospital of Philadelphia.


Gyula Acsadi, MD, PhD
Division Head of Neurology and Rehabilitation
Professor of Pediatric Neurology
Connecticut Children’s Medical Center
University of Connecticut Medical School
Hartford, Connecticut, United States

Dr. Gyula Acsadi serves as a consultant for AveXis, Biogen, and Serepta. He is on the speakers bureau for Biogen and conducts contract research for Biogen, Italfarmaco, and Serepta.


Disclosure Policy

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest

Activity Staff Disclosure

The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.

Accreditation Statement

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The France Foundation designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses who are certified by the American Nurses Credentialing Center (ANCC) may utilize activities that are certified by ACCME-accredited providers toward their requirement for certification renewal by the ANCC. A certificate of attendance will be provided by The France Foundation, an ACCME accredited provider.

Instructions for Receiving Credit

  • There are no fees for participating in and receiving credit for this activity.
  • Review the activity objectives and CME information.
  • Complete the CME activity
  • Complete the online posttest. A score of at least 75% is required to successfully complete this activity. The participant may take the test until successfully passed.
  • Complete the CME evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  • Credit documentation/reporting:
    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME certificate will be available for download.

Statement of Commercial Support

This activity is supported by an educational grant from AveXis, Inc.

Disclaimer Statement

The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.

Disclosure of Unlabeled Use

TFF requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Contact Information for Questions About the Activity

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Pediatrics Presentations

0.50 CME
The France Foundation
Spinal Muscular Atrophy Expert Discussion Conference Series — Questions About SMA Treatment

Spinal Muscular Atrophy Expert Discussion Conference Series — Questions About SMA Treatment

Start

Conference Series: Part 3 of 3

Activity Details

Free CME
0.50 AMA PRA Category 1 Credit(s)
Released: August 21, 2018
Expires: August 20, 2019
30 minutes to complete

Accredited By

Target Audience

Neurologists, pediatric neurologists, neuromuscular specialists, pediatricians, genetic counselors, and other clinicians who see patients with spinal muscular atrophy

Learning Objectives

  • Explain the genetic aspects of SMA, including its recessive nature, carriers, and recommendations for genetic screening
  • Explore the potential implications of gene therapy for SMA
  • Summarize key clinical trial data on available/ emerging treatments for SMA

Activity Description

As new therapies emerge for spinal muscular atrophy (SMA) that include gene replacement and gene modifying therapies, clinicians need to consider the expectations for these treatments. Experts, Dr. Eugenio Mercuri, Dr. Richard Finkel, and Dr. Gyula Acsadi, recently discussed these emerging therapies and their implications on the clinical disease state at an international meeting. This activity is a recording of their roundtable discussion with informative slides broken into 3 parts. The first part discusses diagnosis, genetics, and the role of SMN in SMA. Part 2 explains the results of emerging clinical trial data. The final activity is a practical discussion about the implications of these new therapies for this lethal disease. Discussion topics include the durability of new and emerging treatments and changes to the standards of care for patients with SMA. This education is an engaging update on SMA from the leading experts in the field.

Statement of Educational Need

Many clinicians have questions regarding the genetics of spinal muscular atrophy. In addition, carrier screening is not routinely done, despite ACOG recommendations. Routine newborn testing is currently being considered in many states and internationally. Identification of the neuromotor deficits associated with SMA (and other conditions) is often inaccurate or delayed. As new therapies emerge that include gene replacement and gene modifying therapies, clinicians need to consider the expectations of these treatments. Gene replacement therapy is still a mystery to most clinicians. New therapies prompt a reevaluation of current standards of SMA care.

Agenda

  • What do we know and what do we need to know about treatments?
  • Questions from the audience

Faculty

Eugenio Mercuri, MD, PhD (Chair)
Professor of Pediatric Neurology
Catholic University of the Sacred Heart
Rome, Italy

Dr. Eugenio Mercuri is a consultant for AveXis, Biogen, F. Hoffmann-La Roche, and IONIS. He is a principal investigator for Biogen/IONIS and F. Hoffmann-La Roche studies.


Richard S. Finkel, MD
Division Chief of Neurology
Pediatric Neurology
Nemours Children’s Hospital
Orlando, Florida, United States

Dr. Richard Finkel is a consultant for AveXis, Biogen, Catabasis, Ionis, Mitobridge, Novartis, and Roche. He receives clinical trial support from AveXis, Biogen, Catabasis, Cytokinetics, Ionis, Lilly, MDA, NIH, ReveraGen, and Summit. Dr. Finkel owns stock in Roche. His partner holds several patents and receives patent licensing royalties from National Jewish Center and Children’s Hospital of Philadelphia.


Gyula Acsadi, MD, PhD
Division Head of Neurology and Rehabilitation
Professor of Pediatric Neurology
Connecticut Children’s Medical Center
University of Connecticut Medical School
Hartford, Connecticut, United States

Dr. Gyula Acsadi serves as a consultant for AveXis, Biogen, and Serepta. He is on the speakers bureau for Biogen and conducts contract research for Biogen, Italfarmaco, and Serepta.


Disclosure Policy

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest

Activity Staff Disclosure

The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.

Accreditation Statement

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The France Foundation designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses who are certified by the American Nurses Credentialing Center (ANCC) may utilize activities that are certified by ACCME-accredited providers toward their requirement for certification renewal by the ANCC. A certificate of attendance will be provided by The France Foundation, an ACCME accredited provider.

Instructions for Receiving Credit

  • There are no fees for participating in and receiving credit for this activity.
  • Review the activity objectives and CME information.
  • Complete the CME activity
  • Complete the online posttest. A score of at least 75% is required to successfully complete this activity. The participant may take the test until successfully passed.
  • Complete the CME evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  • Credit documentation/reporting:
    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME certificate will be available for download.

Statement of Commercial Support

This activity is supported by an educational grant from AveXis, Inc.

Disclaimer Statement

The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.

Disclosure of Unlabeled Use

TFF requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Contact Information for Questions About the Activity

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.25 CME
The France Foundation
Spinal Muscular Atrophy Expert Discussion Conference Series — What Causes SMA? Genetics, Diagnosis, and the Role of SMN

Spinal Muscular Atrophy Expert Discussion Conference Series — What Causes SMA? Genetics, Diagnosis, and the Role of SMN

Start

Conference Series: Part 1 of 3

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: August 21, 2018
Expires: August 20, 2019
15 minutes to complete

Accredited By

Target Audience

Neurologists, pediatric neurologists, neuromuscular specialists, pediatricians, genetic counselors, and other clinicians who see patients with spinal muscular atrophy

Learning Objectives

  • Explain the genetic aspects of SMA, including its recessive nature, carriers, and recommendations for genetic screening
  • Describe criteria for SMA diagnosis

Activity Description

As new therapies emerge for spinal muscular atrophy (SMA) that include gene replacement and gene modifying therapies, clinicians need to consider the expectations for these treatments. Experts, Dr. Eugenio Mercuri, Dr. Richard Finkel, and Dr. Gyula Acsadi, recently discussed these emerging therapies and their implications on the clinical disease state at an international meeting. This activity is a recording of their roundtable discussion with informative slides broken into 3 parts. The first part discusses diagnosis, genetics, and the role of SMN in SMA. Part 2 explains the results of emerging clinical trial data. The final activity is a practical discussion about the implications of these new therapies for this lethal disease. Discussion topics include the durability of new and emerging treatments and changes to the standards of care for patients with SMA. This education is an engaging update on SMA from the leading experts in the field.

Statement of Educational Need

Many clinicians have questions regarding the genetics of spinal muscular atrophy. In addition, carrier screening is not routinely done, despite ACOG recommendations. Routine newborn testing is currently being considered in many states and internationally. Identification of the neuromotor deficits associated with SMA (and other conditions) is often inaccurate or delayed. As new therapies emerge that include gene replacement and gene modifying therapies, clinicians need to consider the expectations of these treatments. Gene replacement therapy is still a mystery to most clinicians. New therapies prompt a reevaluation of current standards of SMA care.

Agenda

  • Introduction to SMA
  • Role of SMN1 and SMN2 genes in SMA
  • Role of SMN protein in development

Faculty

Eugenio Mercuri, MD, PhD (Chair)
Professor of Pediatric Neurology
Catholic University of the Sacred Heart
Rome, Italy

Dr. Eugenio Mercuri is a consultant for AveXis, Biogen, F. Hoffmann-La Roche, and IONIS. He is a principal investigator for Biogen/IONIS and F. Hoffmann-La Roche studies.


Richard S. Finkel, MD
Division Chief of Neurology
Pediatric Neurology
Nemours Children’s Hospital
Orlando, Florida, United States

Dr. Richard Finkel is a consultant for AveXis, Biogen, Catabasis, Ionis, Mitobridge, Novartis, and Roche. He receives clinical trial support from AveXis, Biogen, Catabasis, Cytokinetics, Ionis, Lilly, MDA, NIH, ReveraGen, and Summit. Dr. Finkel owns stock in Roche. His partner holds several patents and receives patent licensing royalties from National Jewish Center and Children’s Hospital of Philadelphia.


Gyula Acsadi, MD, PhD
Division Head of Neurology and Rehabilitation
Professor of Pediatric Neurology
Connecticut Children’s Medical Center
University of Connecticut Medical School
Hartford, Connecticut, United States

Dr. Gyula Acsadi serves as a consultant for AveXis, Biogen, and Serepta. He is on the speakers bureau for Biogen and conducts contract research for Biogen, Italfarmaco, and Serepta.


Disclosure Policy

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest

Activity Staff Disclosure

The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.

Accreditation Statement

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The France Foundation designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses who are certified by the American Nurses Credentialing Center (ANCC) may utilize activities that are certified by ACCME-accredited providers toward their requirement for certification renewal by the ANCC. A certificate of attendance will be provided by The France Foundation, an ACCME accredited provider.

Instructions for Receiving Credit

  • There are no fees for participating in and receiving credit for this activity.
  • Review the activity objectives and CME information.
  • Complete the CME activity
  • Complete the online posttest. A score of at least 75% is required to successfully complete this activity. The participant may take the test until successfully passed.
  • Complete the CME evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  • Credit documentation/reporting:
    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME certificate will be available for download.

Statement of Commercial Support

This activity is supported by an educational grant from AveXis, Inc.

Disclaimer Statement

The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.

Disclosure of Unlabeled Use

TFF requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Contact Information for Questions About the Activity

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.50 CME
The France Foundation
Spinal Muscular Atrophy Expert Discussion Conference Series — Transformative Treatment for SMA

Spinal Muscular Atrophy Expert Discussion Conference Series — Transformative Treatment for SMA

Start

Conference Series: Part 2 of 3

Activity Details

Free CME
0.50 AMA PRA Category 1 Credit(s)
Released: August 21, 2018
Expires: August 20, 2019
30 minutes to complete

Accredited By

Target Audience

Neurologists, pediatric neurologists, neuromuscular specialists, pediatricians, genetic counselors, and other clinicians who see patients with spinal muscular atrophy

Learning Objectives

  • Explore the potential implications of gene therapy for SMA
  • Summarize key clinical trial data on available/emerging treatments for SMA

Activity Description

As new therapies emerge for spinal muscular atrophy (SMA) that include gene replacement and gene modifying therapies, clinicians need to consider the expectations for these treatments. Experts, Dr. Eugenio Mercuri, Dr. Richard Finkel, and Dr. Gyula Acsadi, recently discussed these emerging therapies and their implications on the clinical disease state at an international meeting. This activity is a recording of their roundtable discussion with informative slides broken into 3 parts. The first part discusses diagnosis, genetics, and the role of SMN in SMA. Part 2 explains the results of emerging clinical trial data. The final activity is a practical discussion about the implications of these new therapies for this lethal disease. Discussion topics include the durability of new and emerging treatments and changes to the standards of care for patients with SMA. This education is an engaging update on SMA from the leading experts in the field.

Statement of Educational Need

Many clinicians have questions regarding the genetics of spinal muscular atrophy. In addition, carrier screening is not routinely done, despite ACOG recommendations. Routine newborn testing is currently being considered in many states and internationally. Identification of the neuromotor deficits associated with SMA (and other conditions) is often inaccurate or delayed. As new therapies emerge that include gene replacement and gene modifying therapies, clinicians need to consider the expectations of these treatments. Gene replacement therapy is still a mystery to most clinicians. New therapies prompt a reevaluation of current standards of SMA care.

Agenda

  • Gene splicing modifiers
  • Gene replacement therapy MOA
  • Clinical trial results

Faculty

Eugenio Mercuri, MD, PhD (Chair)
Professor of Pediatric Neurology
Catholic University of the Sacred Heart
Rome, Italy

Dr. Eugenio Mercuri is a consultant for AveXis, Biogen, F. Hoffmann-La Roche, and IONIS. He is a principal investigator for Biogen/IONIS and F. Hoffmann-La Roche studies.


Richard S. Finkel, MD
Division Chief of Neurology
Pediatric Neurology
Nemours Children’s Hospital
Orlando, Florida, United States

Dr. Richard Finkel is a consultant for AveXis, Biogen, Catabasis, Ionis, Mitobridge, Novartis, and Roche. He receives clinical trial support from AveXis, Biogen, Catabasis, Cytokinetics, Ionis, Lilly, MDA, NIH, ReveraGen, and Summit. Dr. Finkel owns stock in Roche. His partner holds several patents and receives patent licensing royalties from National Jewish Center and Children’s Hospital of Philadelphia.


Gyula Acsadi, MD, PhD
Division Head of Neurology and Rehabilitation
Professor of Pediatric Neurology
Connecticut Children’s Medical Center
University of Connecticut Medical School
Hartford, Connecticut, United States

Dr. Gyula Acsadi serves as a consultant for AveXis, Biogen, and Serepta. He is on the speakers bureau for Biogen and conducts contract research for Biogen, Italfarmaco, and Serepta.


Disclosure Policy

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest

Activity Staff Disclosure

The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.

Accreditation Statement

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The France Foundation designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses who are certified by the American Nurses Credentialing Center (ANCC) may utilize activities that are certified by ACCME-accredited providers toward their requirement for certification renewal by the ANCC. A certificate of attendance will be provided by The France Foundation, an ACCME accredited provider.

Instructions for Receiving Credit

  • There are no fees for participating in and receiving credit for this activity.
  • Review the activity objectives and CME information.
  • Complete the CME activity
  • Complete the online posttest. A score of at least 75% is required to successfully complete this activity. The participant may take the test until successfully passed.
  • Complete the CME evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  • Credit documentation/reporting:
    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME certificate will be available for download.

Statement of Commercial Support

This activity is supported by an educational grant from AveXis, Inc.

Disclaimer Statement

The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.

Disclosure of Unlabeled Use

TFF requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Contact Information for Questions About the Activity

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.75 CME
Integrity Continuing Education, Inc.
Optimizing the Care of Patients with Severe Asthma through Personalized Disease Management

Optimizing the Care of Patients with Severe Asthma through Personalized Disease Management

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credits
Released: June 25, 2018
Expires: June 25, 2019
45 minutes to complete

Provided By


Integrity Continuing Education, Inc.

Target Audience

This educational initiative has been designed for allergists, pulmonologists, and internal medicine physicians involved in the care of patients with severe asthma.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Identify known phenotypes and endotypes that can inform the development of personalized treatment plans for patients with severe asthma
  • Describe clinical trial data on the efficacy and safety of new and emerging therapies for the treatment of severe asthma
  • Identify strategies for improving communication to promote collaborative decision-making and the ability to self-manage among patients with severe asthma

Activity Description

Despite recent advances in our understanding of the pathophysiology of asthma and a corresponding expansion of targeted treatment modalities, severe asthma care continues to be a challenge in clinical practice. This program is designed to address this issue by imparting clinical knowledge and competence to clinicians that will promote comprehensive assessment and highly personalized treatment of patients whose symptoms meet the criteria for severe asthma. In addition, this educational activity will provide clinicians with guidance on strategies for improving disease awareness, increasing collaborative decision-making, and promoting self-management among patients with severe asthma.

Faculty

J. Mark FitzGerald, MD
Professor of Respiratory Medicine
University of British Columbia
Vancouver, British Columbia


Michael E. Wechsler, MD, MMSc
Professor of Medicine
Director, NJH Cohen Family Asthma Institute
Department of Medicine
National Jewish Health
Denver, Colorado


Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

J. Mark FitzGerald, MD
Consulting Fees: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals, Inc., Merck, Novartis Pharmaceuticals Corporation, TEVA
Speakers Bureaus: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals, Inc., Merck, Novartis Pharmaceuticals Corporation, TEVA
Contracted Research: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals, Inc., GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Sanofi

Michael E. Wechsler, MD, MMSc
Consulting Fees: Amgen, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals, Inc., Genentech, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Sanofi/Regeneron, TEVA
Contracted Research: AstraZeneca Pharmaceuticals LP, Sanofi/Regeneron, TEVA

Patima Tanapat, PhD, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of June 25, 2018 through June 25, 2019 participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 80% or better.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and AstraZeneca Pharmaceuticals LP do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Contact Information for Questions About the Activity

For information about the ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or via email at information@integrityce.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Statement of Commercial Support

This activity is supported by an educational grant from AstraZeneca Pharmaceuticals LP.

1.00 CME
University of California, San Diego School of Medicine
Issues and Updates in Hereditary Angioedema

Issues and Updates in Hereditary Angioedema

Start

Jointly Provided By

University of California, San Diego School of Medicine and RMEI Medical Education, LLC.

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit
Released: December 27, 2017
Expires: December 27, 2018
1.0 hour to complete

Media

Internet

Target Audience

This activity has been designed to meet the educational needs of allergy/immunology physicians, allergy/immunology NPs and PAs, dermatology physicians, dermatology NPs and PAs.

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Recognize the possibility of hereditary angioedema (HAE) in patients who present with angioedema and integrate a diagnostic workup for angioedema that includes analysis for the various types of HAE (Type I, Type II, and normal C1-INH)
  2. Incorporate current, novel, and emerging treatments for HAE based on an understanding of their efficacy, safety, and guidance for use

Activity Description

This interactive multi-challenge activity addresses issues and updates in HAE. Based on the proceedings from a live continuing medical education series, it contains slides, expert audio, and commentary on some of the most current and important topics in HAE. Patient case challenges allow you to test your knowledge and skill in diagnosing and treating this important disease. Commentary from faculty experts will increase your understanding of the newest developments in HAE.

Statement of Educational Need

The treatment of hereditary angioedema (HAE) is rapidly evolving. After many years of limited treatment options, several effective medications for HAE have been introduced into clinical practice over the past 8 years. Now, a second wave of novel therapies are poised to reach the clinic. While the impact of these treatments is not yet known, it is likely the HAE treatment paradigm will shift yet again given the broadening therapeutic options available to physicians and patients.

Faculty

Marc A. Riedl, MD, MS
Professor of Medicine 
Clinical Director, US HAEA Angioedema Center 
Division of Rheumatology, Allergy and Immunology 
University of California, San Diego 
San Diego, CA


Michael E. Manning, MD, FAAAAI, FACAAI
President/Medical Director 
Medical Research of Arizona 
Allergy, Asthma & Immunology Associates, Ltd. 
Scottsdale, AZ


Daniel F. Soteres, MD, MPH
Physician Partner
Asthma & Allergy Associates and Research Center
Colorado Springs, CO


Disclosure of Conflicts of Interest

It is the policy of the University of California, San Diego School of Medicine to ensure balance, independence, objectivity, and scientific rigor. All persons involved in the selection, development, and presentation of content are required to disclose any real or apparent conflicts of interest. All conflicts of interest will be resolved prior to an educational activity being delivered to learners through one of the following mechanisms: 1) altering the financial relationship with the commercial interest, 2) altering the individual’s control over CME content about the products or services of the commercial interest, and/or 3) validating the activity content through independent peer review. All persons are also required to disclose any discussions of off label/unapproved uses of drugs or devices. Persons who refuse or fail to disclose will be disqualified from participating in the CME activity. Participants will be asked to evaluate whether the speaker’s outside interests reflect a possible bias in the planning or presentation of the activity. This information is used to plan future activities.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

  • Marc A. Riedl, MD, MS, has affiliations with CSL Behring, Pharming, Shire (Speakers Bureau); BioCryst, CSL Behring, Ionis, Pharming, Shire (Research); Adverum, Alnylam, BioCryst, CSL Behring, KalVista, Pharming, Shire (Consulting Fees)
  • Michael E. Manning, MD, FAAAAI, FACAAI, has affiliations with CSL Behring, Dyax, Pharming, Shire (Speakers Bureau); BioCryst, CSL Behring, Dyax, Pharming, Shire (Research); CSL Behring, Pharming, Shire (Advisory Board); CSL Behring (Consulting Fees)
  • Daniel F. Soteres, MD, MPH, has affiliations with CSL Behring, Pharming, Shire (Speakers Bureau); CSL Behring, Shire (Research); CSL Behring, Shire (Advisory Board); CSL Behring, Pharming, Shire (Consulting Fees)

The CME staff, meeting planners, and CME committee reviewers do not have any relevant financial relationships to disclose.

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views of the University of California, San Diego.

Physician Continuing Medical Education

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of California, San Diego School of Medicine and RMEI Medical Education, LLC. The University of California, San Diego School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
The University of California, San Diego School of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Cultural Competency
This activity is in compliance with California Assembly Bill 1195 which requires CME courses with patient care components to include curriculum in the subjects of cultural and linguistic competencies. Cultural competency is defined as a set of integrated attitudes, knowledge, and skills that enables healthcare professionals or organizations to care effectively for patients from diverse cultures, groups, and communities. Linguistic competency is defined as the ability of a physician or surgeon to provide patients who do not speak English or who have limited ability to speak English, direct communication in the patient's primary language. Cultural and Linguistic Competency was incorporated into the planning of this activity. Additional resources on cultural and linguistic competency and information about AB1195 can be found on the UC San Diego CME website at http://cme.ucsd.edu.

How to Receive Credit

The estimated time to complete this activity is 1 hour. To obtain credit, participants should view the presentation, answer the multiple-choice post-test questions, and complete the evaluation form online to receive a certificate.

Physicians/DOs who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.

Statement of Commercial Support

The activity is supported in part by educational grants from CSL Behring, Pharming Healthcare, Inc., and Shire.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Hardware/Software Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.

0.50 CME
Postgraduate Institute for Medicine
First Know Thyself: Improving Patient Outcomes in Moderate-to-Severe and Difficult to Treat Pediatric Asthma

First Know Thyself: Improving Patient Outcomes in Moderate-to-Severe and Difficult to Treat Pediatric Asthma

Start

Jointly Provided By

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit
Released: December 12, 2017
Expires: December 12, 2018
30 minutes to complete

Target Audience

Allergy/Immunology and pulmonology clinicians who manage pediatric patients with asthma.

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Optimally utilize recommended therapy algorithms and therapies for asthma in children 6 to 11 years of age based on new data and guidelines
  2. Better define optimal asthma control in childhood in order to implement asthma control
  3. Implement newer and more effective treatment for children with resistant or moderate-to-severe and severe asthma based on efficacy and safety data and different asthma endotypes
  4. Employ a strong patient-provider collaborative approach to managing pediatric patients with asthma that includes patient and caregiver education, engagement, and shared decision making

Faculty

Bradley E. Chipps, MD
Medical Director, Respiratory Therapy and the Cystic Fibrosis Center
Sutter Medical Center
Capital Allergy and Respiratory Disease Center
Sacramento, CA


Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

  • Bradley E. Chipps, MD, has affiliations with AstraZeneca, Boehringer Ingelheim, Circassia, Genentech, Novartis, and TEVA (Consulting Fees).

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

RMEI Medical Education, LLC

  • Jacqui Brooks, MBBCh, MRCPsych, has no affiliations with commercial interests to disclose.
  • Leslie Sharp has no affiliations with commercial interests to disclose.

Postgraduate Institute for Medicine
Planners and Managers
The PIM planners and managers, Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CHCP; Judi Smelker-Mitchek, MBA, MSN, RN; and Jan Schultz, MSN, RN, CHCP, have nothing to disclose.

Physician Continuing Medical Education

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and RMEI Medical Education, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

How to Receive Credit

By reviewing the course content and successfully completing the post-test and evaluation, physicians, nurse practitioners, and physician assistants are entitled to receive up to 0.5 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page. Users must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity evaluation.

Physicians, nurse practitioners, and physician assistants who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.

Statement of Commercial Support

This activity is jointly provided by RMEI Medical Education, LLC and Postgraduate Institute for Medicine. This activity is supported by an educational grant from Genentech.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.